Toronto, Canada
Cynapsus Therapeutics inks a global licensing agreement for certain intellectual property covering all oral films containing apomorphine for the treatment of OFF episodes in Parkinson's disease patients. The deal further strengthens the company's IP covering APL-130277, its investigational sublingual formulation of apomorphine for the treatment of OFF episodes.
Cynapsus Therapeutics (OTCQX:CYNAF) inks a global licensing agreement for certain intellectual property (IP) covering all oral films containing apomorphine for the treatment of OFF episodes in Parkinson's disease (PD) patients. The deal further strengthens the company's IP covering APL-130277, its investigational sublingual (under the tongue) formulation of apomorphine for the treatment of OFF episodes.
Under the terms of the agreement, Monosol Rx will receive an upfront payment, milestones and single-digit royalties on net sales of APL-130277.
APL-130277 is currently in Phase 3 development. The company plans to submit its New Drug Application (NDA) in the U.S. by the end of the year or early 2017.
An OFF episode, a time during which PD patients are unable to perform routine activities like eating, bathing or dressing, is thought to occur when dopamine levels in the brain fall below a certain threshold. It is considered one of the greatest unmet medical needs of PD
sufferershttp://seekingalpha.com/news/3171171-cynapsus-beefs-apomorphine-oral-film-patent-estate-deal-monosol-rx
No comments:
Post a Comment